NCT01367600View on ClinicalTrials.gov

Open-Label Treatment Extension of Protocol MNTX 301

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
Terminal Illness
Interventions
DRUG

SC Methylnaltrexone (MNTX)

Trial Locations (1)

10591

Progenics Pharmaceuticals, Tarrytown

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT01367600 - Open-Label Treatment Extension of Protocol MNTX 301 | Biotech Hunter | Biotech Hunter